Key terms
About ATXI
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATXI news
Apr 03
7:05am ET
Avenue Therapeutics’ AJ201: A Buy Rating for Innovative SBMA Treatment and Promising Clinical Progress
Mar 20
2:01am ET
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
Mar 15
8:23am ET
Avenue Therapeutics granted extension for Nasdaq compliance
Mar 11
8:26am ET
Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting
Feb 24
10:01am ET
Avenue Therapeutics Shareholders Approve Stock Capacity Hike
Feb 22
8:43am ET
Avenue Therapeutics announces publication of preclinical data of BAER-101
Feb 01
7:37am ET
Buy Rating Affirmed for Avenue Therapeutics Amid Strong Prospects for IV Tramadol and Strategic Growth Potential
Jan 24
4:18pm ET
Avenue Therapeutics files to sell 33.08M shares of common stock for holders
Jan 05
9:18am ET
Avenue Therapeutics enters warrant exercise transactions for $5M in procceeds
Jan 04
8:33am ET
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
Jan 03
12:20pm ET
Analysts Conflicted on These Healthcare Names: Avenue Therapeutics (ATXI) and Inovio Pharmaceuticals (INO)
No recent press releases are available for ATXI
ATXI Financials
Key terms
Ad Feedback
ATXI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATXI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range